ArticleThe Clinical biochemist. Reviews2009
Investigating maturity onset diabetes of the young.
Article in The Clinical biochemist. Reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Sociodemographic and biological determinants of insulin initiation in type 2 diabetes: a cohort study using routinely collected primary care data.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- Genetic variants and characterization of MODY in a single, large pediatric referral center.Journal of clinical & translational endocrinology · 2025Article
- Implementing genetic testing in diabetes: Knowledge, perceptions of healthcare professionals, and barriers in a developing country.Population medicine · 2024Article
- Two siblings with a rare type of maturity-onset diabetes of the young (MODY).BMJ case reports · 2023Article
- Review
- Article
- Role of Actionable Genes in Pursuing a True Approach of Precision Medicine in Monogenic Diabetes.Genes · 2022Review
- Genome Editing Human Pluripotent Stem Cells to Model β-Cell Disease and Unmask Novel Genetic Modifiers.Frontiers in endocrinology · 2021Review
- Analysis of the promoter regions of disease-causing genes in maturity-onset diabetes of the young patients.Molecular biology reports · 2020Article
- MODY2 in Asia: analysis of GCK mutations and clinical characteristics.Endocrine connections · 2020Article
- Modeling Monogenic Diabetes using Human ESCs Reveals Developmental and Metabolic Deficiencies Caused by Mutations in HNF1A.Cell stem cell · 2019Article
- Genetic Testing of Maturity-Onset Diabetes of the Young Current Status and Future Perspectives.Frontiers in endocrinology · 2018Review
- Phenotype Heterogeneity in Glucokinase-Maturity-Onset Diabetes of the Young (GCK-MODY) Patients.Journal of clinical research in pediatric endocrinology · 2017Article
- Current progress of genetically engineered pig models for biomedical research.BioResearch open access · 2014Review
- Genetically engineered pig models for diabetes research.Transgenic research · 2014Review
- Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families.Kidney international · 2014Article
- Frequency and genetic spectrum of maturity-onset diabetes of the young (MODY) in southern New Zealand.Journal of diabetes and metabolic disorders · 2013Article
- Specification of hepatopancreas progenitors in zebrafish by hnf1ba and wnt2bb.Development (Cambridge, England) · 2013Article
- Glucokinase (GCK) mutations and their characterization in MODY2 children of southern Italy.PloS one · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maturity Onset Diabetes of Young (MODY) is a monogenic and autosomal dominant form of diabetes mellitus with onset of the disease often before 25 years of age. It is due to dysfunction of pancreatic beta cells characterised by non-ketotic diabetes and absence of pancreatic auto-antibodies. It is frequently mistaken for type 1 or type 2 diabetes mellitus. Diagnosis of MODY is important as the GCK subtype has better prognosis and may not require any treatment. Subtypes HNF1A and HNF4A are sensitive to sulfonylureas, however diabetes complications are common if not treated early. Moreover, there is genetic implication for the patient and family. Rare MODY subtypes can be associated with pancreatic and renal anomalies as well as exocrine dysfunction of the pancreas. So far there are six widely accepted subtypes of MODY described but the list has grown to nine. Although the majority of diabetes mellitus in youth remains type 1 and the incidence of type 2 is rising, MODY should be considered in patients with non-ketotic diabetes at presentation, and in patients with a strong family history of diabetes mellitus without pancreatic auto-antibodies. Furthermore the diagnosis must be confirmed by molecular studies. With advancement in genomic technology, rapid screening for MODY mutations will become readily available in the future.
Identifiers
19565026PMC2702215W1503093358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.